2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow iratumumab: new trials by email Literature Review of iratumumab trials Research Report on iratumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma MDX-060 - Lymphoma, Large-Cell | Phase 2 | Withdrawn | Bristol-Myers Squibb | 45 | 2006-02-01 | 2010-04-26 |
| A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease MDX-060 - Hodgkin's Disease | Phase 2 | Completed | Bristol-Myers Squibb | 74 | 2005-11-01 | 2015-10-12 |
| MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma iratumumab - Lymphoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2003-01-01 | 2013-05-30 |
Dendritic Cell Sarcoma, Interdigitating (2) · Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, Large-Cell, Anaplastic (2) · Recurrence (2) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
Bristol-Myers Squibb (2) · Memorial Sloan Kettering Cancer Center (1)
United States (3) · France (1)